Pharma giant Jazz dismisses final patent claim involving cannabinoid epilepsy drug
Global pharma company Jazz Pharmaceuticals has ended patent claims related to its cannabinoid-based epilepsy drug, Epidiolex.
News February 11
Latest In: GW Pharmaceuticals
Cannabinoid-based medicine Epidiolex approved for sale in Canada
Canada's federal health regulator has approved Jazz Pharmaceuticals Canada's cannabinoid-based medicine Epidiolex as an adjunctive therapy for certain…
News November 30
Court tosses Canopy cannabis patent infringement lawsuit against GW Pharma
A Texas court has dismissed a lawsuit brought by Canadian cannabis producer Canopy Growth against GW Pharmaceuticals, although…
News March 2
How will inflation impact cannabis retail + two deals that illustrate industry change
While wholesale cannabis prices have been going up - sometimes as much as 30%, according to a recent…
News December 22
Intellectual property takes on growing role in cannabis industry deals
Intellectual property is playing an increasingly important role in cannabis industry acquisitions and other deals as businesses look…
News April 5
Medical cannabinoid firm GW Pharma to be acquired by Jazz Pharmaceuticals for $7.2 billion
Global pharma company Jazz Pharmaceuticals has reached an agreement to buy U.K.-based GW Pharmaceuticals, one of the largest…
News February 3
GW Pharma expects fiscal 2020 sales to reach $526 million
United Kingdom-based GW Pharmaceuticals expects to report annual sales of roughly $526 million for the year ended Dec.…
News January 13
Denmark medical cannabis sales post a positive quarter thanks to Epidiolex
Sales of medical marijuana in Denmark posted healthy gains in the third quarter of 2020, coinciding with the…
News January 7
Cannabis firm Canopy Growth sues GW Pharma, claiming patent infringement
Canadian cannabis producer Canopy Growth Corp. is suing Britain's GW Pharmaceuticals in U.S. federal court, alleging that GW…
News December 23Featured
Latest Sponsored
